Table 2. Change in brain glutathione levels (as GSH/Cr peak ratios) relative to baseline after 200 mg nasally administered GSH.
|
Glutathione level (GSH/Cr peak ratio) |
|||||
|---|---|---|---|---|---|
| Time post dose (min) as midpoint of scan (s.e.m.) | Subjects (n=15) | Mean (s.e.m.) | Min | Max | Mean difference relative to baseline (s.e.m.) |
| 0 (baseline) | 15a | 0.0170 (0.0046) | 0.0035 | 0.0620 | |
| 7.5 (0.0) | 15 | 0.0259 (0.0039) | 0.0080 | 0.0580 | 0.00890 (0.00507) |
| 19.9 (0.17) | 14 | 0.0364 (0.0057) | 0.0120 | 0.0760 | 0.0201 (0.00585) |
| 32.0 (0.17) | 15 | 0.0385 (0.0053) | 0.0130 | 0.0810 | 0.0215 (0.00532) |
| 44.7 (0.22) | 9 | 0.0457 (0.012) | 0.0130 | 0.114 | 0.0340 (0.0135) |
Abbreviations: GSH, glutathione; Cr, creatine.
a
For the baseline scans where the GSH peak was undetectable, a GSH/Cr value (lowest measured value/2) was substituted, as described in the Materials and Methods section.
For six subjects, baseline GSH levels were undetectable, and one post-dose spectrum from one subject was omitted owing to poor data quality.